OBJECTIVES: To examine "real world" treatments for patients with mild cognitive impairment (MCI). DESIGN: Cross-sectional. SETTING: California Department of Public Health Alzheimer's Disease (AD) Research Centers of California. PARTICIPANTS: Five hundred seventy-eight patients diagnosed with MCI. MEASUREMENTS: All patients underwent comprehensive neurological and neuropsychological evaluations. Logistic regression models were used to determine patient characteristics associated with use of anti-AD medications, statins, antioxidants, and folic acid. RESULTS: One hundred sixty-six patients (28.7%) were taking anti-AD medications; use was associated with greater functional impairment, higher education, MCI subtype, and older age (P<.05 for all). Two hundred fifty-two patients (43.6%) were taking statins; use was associated with diabetes mellitus, hypertension, myocardial infarct, male sex, and MCI subtype (P<.05 for all). One hundred fifteen patients (19.9%) were taking antioxidants; use was associated with higher education and diabetes mellitus and varied according to site (P<.05 for all). Thirty-seven patients (6.4%) were taking folic acid; use was associated with nonwhite race, male sex, and greater functional impairment (P<.05 for all). CONCLUSION: This study suggests that patients with MCI are frequently being treated with "off label" cholinesterase inhibitors and memantine, as well as other possible cognition-enhancing drugs. Further investigation of the effect of treatment patterns on the clinical course of MCI is needed.
OBJECTIVES: To examine "real world" treatments for patients with mild cognitive impairment (MCI). DESIGN: Cross-sectional. SETTING: California Department of Public Health Alzheimer's Disease (AD) Research Centers of California. PARTICIPANTS: Five hundred seventy-eight patients diagnosed with MCI. MEASUREMENTS: All patients underwent comprehensive neurological and neuropsychological evaluations. Logistic regression models were used to determine patient characteristics associated with use of anti-AD medications, statins, antioxidants, and folic acid. RESULTS: One hundred sixty-six patients (28.7%) were taking anti-AD medications; use was associated with greater functional impairment, higher education, MCI subtype, and older age (P<.05 for all). Two hundred fifty-two patients (43.6%) were taking statins; use was associated with diabetes mellitus, hypertension, myocardial infarct, male sex, and MCI subtype (P<.05 for all). One hundred fifteen patients (19.9%) were taking antioxidants; use was associated with higher education and diabetes mellitus and varied according to site (P<.05 for all). Thirty-seven patients (6.4%) were taking folic acid; use was associated with nonwhite race, male sex, and greater functional impairment (P<.05 for all). CONCLUSION: This study suggests that patients with MCI are frequently being treated with "off label" cholinesterase inhibitors and memantine, as well as other possible cognition-enhancing drugs. Further investigation of the effect of treatment patterns on the clinical course of MCI is needed.
Authors: H C Chui; W Mack; J E Jackson; D Mungas; B R Reed; J Tinklenberg; F L Chang; K Skinner; C Tasaki; W J Jagust Journal: Arch Neurol Date: 2000-02
Authors: David J Stott; Graham MacIntosh; Gordon D O Lowe; Ann Rumley; Alex D McMahon; Peter Langhorne; R Campbell Tait; Denis St J O'Reilly; Edward G Spilg; Jonathan B MacDonald; Peter W MacFarlane; Rudi G J Westendorp Journal: Am J Clin Nutr Date: 2005-12 Impact factor: 7.045
Authors: James Shepherd; Gerard J Blauw; Michael B Murphy; Edward L E M Bollen; Brendan M Buckley; Stuart M Cobbe; Ian Ford; Allan Gaw; Michael Hyland; J Wouter Jukema; Adriaan M Kamper; Peter W Macfarlane; A Edo Meinders; John Norrie; Chris J Packard; Ivan J Perry; David J Stott; Brian J Sweeney; Cillian Twomey; Rudi G J Westendorp Journal: Lancet Date: 2002-11-23 Impact factor: 79.321
Authors: Paul S Aisen; Lon S Schneider; Mary Sano; Ramon Diaz-Arrastia; Christopher H van Dyck; Myron F Weiner; Teodoro Bottiglieri; Shelia Jin; Karen T Stokes; Ronald G Thomas; Leon J Thal Journal: JAMA Date: 2008-10-15 Impact factor: 56.272
Authors: Jared R Tinklenberg; Helena C Kraemer; Kristine Yaffe; Leslie Ross; Javaid Sheikh; John W Ashford; Jerome A Yesavage; Joy L Taylor Journal: Am J Geriatr Psychiatry Date: 2007-11 Impact factor: 4.105
Authors: B Winblad; S Gauthier; L Scinto; H Feldman; G K Wilcock; L Truyen; A J Mayorga; D Wang; H R Brashear; J S Nye Journal: Neurology Date: 2008-03-05 Impact factor: 9.910
Authors: Jared R Tinklenberg; Helena C Kraemer; Kristine Yaffe; Ruth O'Hara; John M Ringman; John W Ashford; Jerome A Yesavage; Joy L Taylor Journal: Am J Geriatr Psychiatry Date: 2014-09-28 Impact factor: 4.105
Authors: Andrea L Weston; Andrea M Weinstein; Cynthia Barton; Kristine Yaffe Journal: J Gerontol A Biol Sci Med Sci Date: 2009-10-20 Impact factor: 6.053
Authors: J Winchester; M B Dick; D Gillen; B Reed; B Miller; J Tinklenberg; D Mungas; H Chui; D Galasko; L Hewett; C W Cotman Journal: Arch Gerontol Geriatr Date: 2012-09-05 Impact factor: 3.250